<DOC>
	<DOCNO>NCT02824224</DOCNO>
	<brief_summary>This study evaluate ability tamoxifen improve frequent prolong bleed new user 52mg levonorgestrel-releasing intrauterine device . Half participant receive course tamoxifen three week insertion IUD , half participant receive course placebo .</brief_summary>
	<brief_title>Tamoxifen Reduce Unscheduled Bleeding New Users Levonorgestrel-releasing Intrauterine System ( LNG-IUS )</brief_title>
	<detailed_description>New user LNG IUS eligible . Subjects randomize receive tamoxifen 10 mg BID 7 day placebo . Study drug start 3 week placement IUS . Subjects maintain record daily bleed spot use electronic text message diary .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>initiate use 52mg levonorgestrelreleasing IUD contraceptive purpose access reliable cell phone willing receive respond daily text email message ass bleed use IUD indication contraception postpartum within 6 month , pregnant , breastfeed removal replacement IUD undiagnosed abnormal uterine bleeding prior placement IUD bleeding dyscrasia anticoagulation use active cervicitis allergy tamoxifen history venous thromboembolism personal history breast uterine malignancy use medication contraindicate use tamoxifen ( coumadin , letrozole , bromocriptine , rifampicin , aminoglutethimide , phenobarbital )</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>levonorgestrel</keyword>
	<keyword>breakthrough bleeding</keyword>
</DOC>